These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2570046)

  • 1. Dynorphin deficiency in Tourette's syndrome.
    Sandyk R
    Int J Neurosci; 1989 May; 46(1-2):65-6. PubMed ID: 2570046
    [No Abstract]   [Full Text] [Related]  

  • 2. Deregulation of hypothalamic opioid and luteinizing hormone releasing factor (LHRF) activity and its relevance to Tourette's syndrome.
    Sandyk R; Bamford CR
    Int J Neurosci; 1988 Apr; 39(3-4):223-4. PubMed ID: 3045034
    [No Abstract]   [Full Text] [Related]  

  • 3. Clomiphene citrate in Tourette's syndrome.
    Sandyk R; Bamford CR; Laguna J
    Postgrad Med J; 1987 Jun; 63(740):510-1. PubMed ID: 3481073
    [No Abstract]   [Full Text] [Related]  

  • 4. Clomiphene citrate in Tourette's syndrome.
    Sandyk R
    Int J Neurosci; 1988 Nov; 43(1-2):103-6. PubMed ID: 3215725
    [No Abstract]   [Full Text] [Related]  

  • 5. Inhibition of prolactin release by luteinizing hormone-releasing hormone in Tourette's syndrome.
    Sandyk R; Bamford CR
    Int J Neurosci; 1988 Jun; 40(3-4):217-8. PubMed ID: 3042658
    [No Abstract]   [Full Text] [Related]  

  • 6. Isolated gonadotropin deficiency. A heterogenous syndrome.
    Spitz IM; Diamant Y; Rosen E; Bell J; David MB; Polishuk W; Rabinowitz D
    N Engl J Med; 1974 Jan; 290(1):10-5. PubMed ID: 4586101
    [No Abstract]   [Full Text] [Related]  

  • 7. Some studies with gonadotrophin releasing hormone in amenorrhoeic and anovulatory patients.
    Matthews CD; Cox LW; Symons RG
    Aust N Z J Obstet Gynaecol; 1975 Nov; 15(4):228-33. PubMed ID: 786248
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of clomiphene citrate on plasma levels of immunoreactive luteinizing hormone-releasing hormone, gonadotropin, and testosterone in normal subjects and in patients with idiopathic oligospermia.
    Masala A; Delitala G; Alagna S; Devilla L; Lotti G
    Fertil Steril; 1978 Apr; 29(4):424-7. PubMed ID: 348501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The central role of magnesium deficiency in Tourette's syndrome: causal relationships between magnesium deficiency, altered biochemical pathways and symptoms relating to Tourette's syndrome and several reported comorbid conditions.
    Grimaldi BL
    Med Hypotheses; 2002 Jan; 58(1):47-60. PubMed ID: 11863398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gilles de la Tourette's syndrome. A postmortem neuropathological and immunohistochemical study.
    Haber SN; Kowall NW; Vonsattel JP; Bird ED; Richardson EP
    J Neurol Sci; 1986 Sep; 75(2):225-41. PubMed ID: 2428943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PET studies of the presynaptic and postsynaptic dopaminergic system in Tourette's syndrome.
    Turjanski N; Sawle GV; Playford ED; Weeks R; Lammerstma AA; Lees AJ; Brooks DJ
    J Neurol Neurosurg Psychiatry; 1994 Jun; 57(6):688-92. PubMed ID: 7911827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pharmacotherapeutic rationale for the use of lithium carbonate in Tourette's syndrome.
    Messiha FS
    Proc West Pharmacol Soc; 1979; 22():27-9. PubMed ID: 292979
    [No Abstract]   [Full Text] [Related]  

  • 13. A controlled trial of propoxyphene and naltrexone in patients with Tourette's syndrome.
    Kurlan R; Majumdar L; Deeley C; Mudholkar GS; Plumb S; Como PG
    Ann Neurol; 1991 Jul; 30(1):19-23. PubMed ID: 1681781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Post-pubertal secondary amenorrhea. Study of the hypothalamo-hypophyseal axis by the sequential use of clomiphene-LH-RH].
    Herreros I; Guadalix F; Charro A; Botella J
    Ann Endocrinol (Paris); 1977; 38(5):343-50. PubMed ID: 341777
    [No Abstract]   [Full Text] [Related]  

  • 15. Cerebrospinal fluid dynorphin A[1-8] and beta-endorphin levels in Tourette's syndrome are unaltered.
    van Wattum PJ; Anderson GM; Chappell PB; Goodman WK; Riddle MA; Leckman JF
    Biol Psychiatry; 1999 Jun; 45(11):1527-8. PubMed ID: 10356639
    [No Abstract]   [Full Text] [Related]  

  • 16. Gilles de la Tourette's syndrome: biochemical approaches.
    Van Woert MH; Jutkowitz R; Rosenbaum D; Bowers MB
    Res Publ Assoc Res Nerv Ment Dis; 1976; 55():459-65. PubMed ID: 1070064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of methylphenidate and imipramine in Gilles de la Tourette's disease in children.
    Fras I; Karlavage J
    Am J Psychiatry; 1977 Feb; 134(2):195-7. PubMed ID: 264771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated CSF dynorphin A [1-8] in Tourette's syndrome.
    Leckman JF; Riddle MA; Berrettini WH; Anderson GM; Hardin M; Chappell P; Bissette G; Nemeroff CB; Goodman WK; Cohen DJ
    Life Sci; 1988; 43(24):2015-23. PubMed ID: 2463450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The hypothalamic luteinizing hormone releasing hormone "pulse generator" and the opioid system in Tourette's syndrome.
    Sandyk R; Bamford CR
    Int J Neurosci; 1988 Jul; 41(1-2):81-2. PubMed ID: 3137184
    [No Abstract]   [Full Text] [Related]  

  • 20. A study of endogenous dopamine metabolism in Gilles de la Tourette's disease.
    Messiha FS; Knopp W
    Dis Nerv Syst; 1976 Aug; 37(8):470-3. PubMed ID: 1066216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.